Medical Crossfire®: Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

Activity Overview

Non–muscle-invasive bladder cancer (NMIBC) represents the majority of newly-diagnosed bladder cancers, and it remains associated with high rates of recurrence and progression despite standard therapies. Management is increasingly complex due to ongoing shortages of Bacillus Calmette-Guerin vaccine, limited durability of conventional intravesical treatments, and the rapid emergence of novel immunotherapies, gene therapies, and advanced drug-delivery platforms. Clinicians continue to face challenges in risk stratification, treatment sequencing, and integrating newly approved and investigational agents into personalized care plans.

This continuing medical education–certified program is delivered using the Medical Crossfire® format, which leverages expert debate and multidisciplinary discussion to translate emerging clinical data into practical, real-world decision-making. The virtual format enables broad participation by urologists, medical oncologists, and advanced practice providers and facilitates timely education and interactive exchange on evolving NMIBC treatment strategies without geographic barriers.

This educational activity is an archive of the live virtual symposium held on February 23, 2026.

Target Audience

This educational program is directed toward medical oncologists, urologists, radiologists, and other physicians who are interested in the treatment of NMIBC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Implement best practices for the accurate diagnosis and risk stratification of non–muscle-invasive bladder cancer (NMIBC)
• Describe the mechanisms of action and supporting clinical trial data for recently approved and emerging therapies in NMIBC
• Integrate novel therapies into personalized care plans for patients with NMIBC
• Apply multidisciplinary care strategies to optimize outcomes in patients with NMIBC, including management of treatment-related adverse events and effective coordination of care